Raia Drogasil SA Stock Sao Paulo
Stocks
DROG3
BRDROGACNOR1
Drug Retailers
OTC Markets Traded|
End-of-day quote
Sao Paulo
|
||
| - BRL | - |
|
| 08-05 | Raia Drogasil S.A., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 08-04 | Raia Drogasil S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 32.26B 6.21B 5.47B 5.15B 4.7B 8.79B 597B 8.86B 61.84B 23.96B 304B 23.33B 22.83B 988B | P/E 2026 * |
21.6x | P/E 2027 * | 16.2x |
|---|---|---|---|---|---|
| Enterprise Value | 40.35B 7.77B 6.84B 6.44B 5.88B 11B 746B 11.08B 77.34B 29.97B 380B 29.18B 28.55B 1,236B | EV / Sales 2026 * |
0.89x | EV / Sales 2027 * | 0.79x |
| Free-Float |
73.04% | Yield 2026 * |
2.05% | Yield 2027 * | 2.34% |
Last Transcript: Raia Drogasil SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2024-12-31 | |
| Director of Finance/CFO | 63 | 2013-04-28 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 50 | 2024-12-31 | |
| Director/Board Member | - | - | |
Gilberto Lerio
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.53% | -9.29% | +2.95% | -31.39% | 6.63B | |
| -1.44% | -1.96% | -22.20% | +21.40% | 1.23B | |
| +2.47% | +2.30% | +19.26% | +28.78% | 557M | |
| +0.50% | +0.36% | -11.13% | +26.99% | 66.23M | |
| Average | -1.25% | -0.77% | -2.78% | +11.44% | 2.12B | |
| Weighted average by Cap. | -5.15% | -3.23% | +0.27% | -19.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45.4B 8.75B 7.69B 7.25B 6.62B 12.37B 840B 12.47B 87.03B 33.73B 427B 32.84B 32.13B 1,391B | 51.87B 9.99B 8.79B 8.29B 7.56B 14.14B 959B 14.25B 99.43B 38.53B 488B 37.52B 36.7B 1,589B |
| Net income | 1.51B 290M 255M 241M 219M 410M 27.85B 414M 2.89B 1.12B 14.17B 1.09B 1.07B 46.12B | 2.02B 389M 342M 322M 294M 550M 37.3B 554M 3.87B 1.5B 18.99B 1.46B 1.43B 61.78B |
| Net Debt | 8.09B 1.56B 1.37B 1.29B 1.18B 2.2B 150B 2.22B 15.5B 6.01B 76.09B 5.85B 5.72B 248B | 8.97B 1.73B 1.52B 1.43B 1.31B 2.45B 166B 2.46B 17.2B 6.66B 84.43B 6.49B 6.35B 275B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RADL3 Stock
- DROG3 Stock
Select your edition
All financial news and data tailored to specific country editions
